Agilent/$A

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Agilent

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Ticker

$A
Sector

Primary listing

NYSE

Employees

18,000

Agilent Metrics

BasicAdvanced
$36B
29.33
$4.28
-
$0.98
0.79%

What the Analysts think about Agilent

Analyst ratings (Buy, Hold, Sell) for Agilent stock.

Bulls say / Bears say

Agilent posted $1.7 billion in Q2 revenue, beating the $1.6 billion FactSet consensus, and raised its full-year revenue outlook to $6.73–$6.81 billion, reflecting strong demand and operational execution (Barron’s)
Despite funding cuts to U.S. academic labs, Agilent’s academia & government sales declined only 2% in Q2, better than peers and highlighting resilience in high-stickiness markets (Barron’s)
The Agilent CrossLab segment grew 7% reported and 9% core in Q2 with a 32.4% operating margin, driven by robust consumables and services demand (Nasdaq)
Agilent warned that higher U.S. duties would financially impede its operations and limit reinvestment in R&D and support functions, underscoring tariff-related profitability risks (Reuters)
Agilent’s academia and government segment fell 2% year-over-year in Q2, reflecting persistent funding pressures in a key, stickier end market (Barron’s)
The Applied Markets segment recorded a 1% revenue decline and flat core growth in Q2, signaling stagnating demand for gas chromatography and spectroscopy instruments (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

Agilent Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Agilent Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $A

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Agilent stock | $A Share Price | Lightyear